greeksoup/ stocks
Stocks / United States / BMY / Q3 FY2023

Bristol-Myers Squibb Co. Q3 FY2023 results: revenue $11.0 billion, down 2.2% on the year

Bristol-Myers Squibb Co. (BMY) reported revenue of $11.0 billion for Q3 FY2023, the quarter ended 30 September 2023, down 2.2% on the same quarter a year earlier. Net income was $1.9 billion, up 20.0% on the year, and diluted earnings per share $0.93. The figures are the company's own, from the 10-Q it filed with the SEC on 26 October 2023.

Revenue$11.0 billiondown 2.2%
Net income$1.9 billionup 20.0%
Diluted EPS$0.93
QuarterQ3 FY2023ended 30 September 2023

The quarter, against the one before and a year earlier

LineQ3 FY2023Quarter beforeA year earlierChange on the year
Revenue10,966n/an/an/a
Cost of revenue2,506n/an/an/a
Gross profit8,460n/an/an/a
Gross margin77.1%n/an/a
Research and development2,242n/an/an/a
Selling, general and administrative2,003n/an/an/a
Operating income2,137n/an/an/a
Operating margin19.5%n/an/a
Interest expense280n/an/an/a
Pre-tax income2,137n/an/an/a
Income tax203n/an/an/a
Effective tax rate9.5%n/an/a
Net income1,928n/an/an/a
Net margin17.6%n/an/a
Diluted EPS$0.93n/an/an/a

$ million except per share. Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.

Cash flow and capital returned

LineQ3 FY2023Quarter beforeA year earlierChange on the year
Operating cash flow4,751n/an/an/a
Capital expenditure342n/an/an/a
Free cash flow4,409n/an/an/a
Free cash flow margin40.2%n/an/a
Depreciation and amortisation2,451n/an/an/a
Share-based compensation132n/an/an/a
Buybacks4,000n/an/an/a
Dividends paid1,191n/an/an/a
Dividend per share$0.57n/an/an/a
Diluted shares, weighted2,064mn/an/an/a
Shares outstanding at period end2,035mn/an/an/a

Cash flow lines for the quarter; where the company files them year to date, the quarter is the difference between two filings.

Balance sheet at quarter end

LineQ3 FY2023Quarter beforeA year earlierChange on the year
Total assets91,263n/an/an/a
Cash and equivalents7,514n/an/an/a
Receivables8,407n/an/an/a
Inventory2,436n/an/an/a
Goodwill21,147n/an/an/a
Long-term debt37,010n/an/an/a
Operating lease liabilities1,513n/an/an/a
Shareholders' equity28,998n/an/an/a

Quarterly results, the last 12 quarters

Q3 FY2023Q4 FY2023 *Q1 FY2024Q2 FY2024Q3 FY2024Q4 FY2024 *Q1 FY2025Q2 FY2025Q3 FY2025Q4 FY2025 *Q1 FY2026Q2 FY2026
Revenue10,96611,47711,86512,20111,89212,34211,20112,26912,22212,50211,48912,973
Cost of revenue2,5062,7452,9323,2672,9574,8123,0333,3723,4354,0963,4213,726
Gross profit8,4608,7328,9338,9348,9357,5308,1688,8978,7878,4068,0689,247
Gross margin77%76%75%73%75%61%73%73%72%67%70%71%
R&D2,2422,4782,6952,8992,3743,1912,2572,5802,5282,5862,6492,959
SG&A2,0032,0732,3671,9281,9832,1361,5841,7131,7892,1811,6171,826
Operating income2,1371,674-11,5161,2861,6761752,9711,7733,1141,4703,2394,086
Operating margin19%15%-97%11%14%1%27%14%25%12%28%31%
Interest expense280316425521505496494485480432411407
Pre-tax income2,1371,674-11,5161,2861,6761752,9711,7733,1141,4703,2404,086
Tax rate9%-5%n/a-31%28%57%17%26%30%26%17%19%
Net income1,9281,762-11,9111,6801,21172.02,4561,3102,2011,0872,6773,317
Net margin18%15%-100%14%10%1%22%11%18%9%23%26%
Diluted EPS$0.93$0.87-$5.89$0.83$0.60$0.05$1.20$0.64$1.08$0.54$1.31$1.62
Operating cash flow4,7514,2522,8342,3265,5914,4391,9543,9176,3111,9741,1043,393
Capital expenditure342330284262324378260361320370347305
Free cash flow4,4093,9222,5502,0645,2674,0611,6943,5565,9911,6047573,088
Buybacks4,0000.00.00.00.00.0n/an/an/an/an/an/a
Dividends paid1,1911,1601,2121,2171,2161,2181,2581,2621,2631,2621,2831,287
Shares outstanding2,035m2,022m2,027m2,027m2,028m2,029m2,035m2,035m2,036m2,036m2,042m2,043m
Filing10-Q10-K10-Q10-Q10-Q10-K10-Q10-Q10-Q10-K10-Q10-Q

* The fourth quarter is the full year less the first three quarters, because the company files the year and not the quarter on its own. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and the share count are as they are. Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Cash flow lines filed year to date are the difference between two filings. Shares outstanding are at the period end where the balance sheet tags them, otherwise the count on the filing's cover page. A derived fourth-quarter EPS is left blank when a split in the year makes the arithmetic meaningless.

Source

10-Q for the period ended 30 September 2023, filed 26 October 2023, accession 0000014272-23-000181: the filing on EDGAR. All of Bristol-Myers Squibb Co.'s filings: EDGAR company page.

The same record on your computer

GreekSoup is also a free program for your own computer. It reads these same filings for the names you follow, refreshed as they land, with no account. One pasted line installs it.

Install